XML 35 R20.htm IDEA: XBRL DOCUMENT v3.23.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2023 and 2022:

			Three months ended March 31,
			2023						2022
Products:
Kristalose			$	4,315,128					$	3,945,097
Sancuso			1,886,793						3,397,209
Vibativ			1,848,187						2,501,434
Caldolor			935,043						959,634
Acetadote			169,856						111,090
Vaprisol			16,008						(117,000)
Omeclamox-Pak			(2,518)						22,737
RediTrex			(141,045)						59,226
Other revenue			197,186						295,618
Total net revenues			$	9,224,638					$	11,175,045

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration